Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients - a Randomized Non-blinded Two-arm Phase III Prospective Clinical Trial (TAB-2 Study).

NCT07062263 is registered in ClinicalTrials.gov with Tata Memorial Centre as lead sponsor.

NCT NCT07062263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07062263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients - a Randomized Non-blinded Two-arm Phase III Prospective Clinical Trial (TAB-2 Study).
Lead sponsor
Tata Memorial Centre
Phase
Phase 3
Overall status
Recruiting
Start date
July 21, 2023
Completion date
July 31, 2029
Enrollment
220 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, biliary tract cancer, her2-positive cancer, metastatic biliary tract carcinoma, unresectable biliary tract carcinoma